Cme 265 15 Mar 32 Bond Price To Sales
| 12572QAK1 | 85.05 3.31 3.75% |
CME 265 15 MAR 32 fundamentals help investors to digest information that contributes to 12572QAK1's financial success or failures. It also enables traders to predict the movement of 12572QAK1 Bond. The fundamental analysis module provides a way to measure 12572QAK1's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to 12572QAK1 bond.
12572QAK1 |
CME 265 15 MAR 32 Corporate Bond Price To Sales Analysis
12572QAK1's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Based on the latest financial disclosure, CME 265 15 MAR 32 has a Price To Sales of 0.0 times. This indicator is about the same for the average (which is currently at 0.0) sector and about the same as Price To Sales (which currently averages 0.0) industry. This indicator is about the same for all United States bonds average (which is currently at 0.0).
12572QAK1 Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses 12572QAK1's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the bonds which would be a good addition to a portfolio. Peer analysis of 12572QAK1 could also be used in its relative valuation, which is a method of valuing 12572QAK1 by comparing valuation metrics of similar companies.CME 265 cannot be rated in Price To Sales category at this point.
About 12572QAK1 Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CME 265 15 MAR 32's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of 12572QAK1 using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CME 265 15 MAR 32 based on its fundamental data. In general, a quantitative approach, as applied to this corporate bond, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in 12572QAK1 Bond
12572QAK1 financial ratios help investors to determine whether 12572QAK1 Bond is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in 12572QAK1 with respect to the benefits of owning 12572QAK1 security.